Sisram Medical Announces Completion of NIFDC Testing for DAXXIFY in China

Sisram Medical Ltd., a global leader in medical aesthetic solutions, has announced that its long‑acting botulinum toxin type A product **DAXXIFY** has successfully completed quality testing by the **National Institutes for Food and Drug Control of the People’s Republic of China (NIFDC)**, marking a pivotal regulatory milestone ahead of its market launch in mainland China. This achievement confirms that DAXXIFY meets China’s stringent national drug regulatory standards for quality, safety, and efficacy, and represents the final required step before commercialization. The product, known for its proprietary Peptide Exchange Technology (PXT) and stabilized peptide formulation, is designed to deliver rapid onset and long‑lasting effects for the temporary improvement of moderate to severe glabellar lines. Having secured initial commercial orders from key medical aesthetic institutions, Sisram is transitioning from the preparation phase into the sales phase. To support the product’s introduction, Sisram has also established dedicated teams for market expansion, clinical support and supply chain management, and partnered with industry players such as Fosun Wanbang and Shanghai Pharmaceuticals to ensure a reliable and compliant distribution system. Sisram expects DAXXIFY to become a cornerstone of its injectable portfolio in China, reinforcing the company’s strategic growth in the medical aesthetics market. #DAXXIFY #SisramMedical #MedicalAesthetics #ChinaLaunch #SlimScan #GrowthStocks #CANSLIM